Clinical Trial Update: A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II clinical study evaluating HLX43 in advanced pancreatic ductal adenocarcinoma; trial status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Status: NOT_YET_RECRUITING